Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Equivalents (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Cash & Equivalents for 15 consecutive years, with $21.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 45.57% year-over-year to $21.9 million, compared with a TTM value of $21.9 million through Sep 2025, down 45.57%, and an annual FY2024 reading of $26.6 million, up 100.72% over the prior year.
  • Cash & Equivalents was $21.9 million for Q3 2025 at Fennec Pharmaceuticals, down from $22.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $51.2 million in Q1 2024 and bottomed at $12.4 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $26.2 million, with a median of $23.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 285.74% in 2024, then tumbled 55.7% in 2025.
  • Year by year, Cash & Equivalents stood at $27.3 million in 2021, then decreased by 12.89% to $23.8 million in 2022, then crashed by 44.19% to $13.3 million in 2023, then surged by 100.72% to $26.6 million in 2024, then fell by 17.6% to $21.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for FENC at $21.9 million in Q3 2025, $22.7 million in Q1 2025, and $26.6 million in Q4 2024.